51 related articles for article (PubMed ID: 38766320)
1. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.
Yankah RK; Anku EK; Eligar V
J Diabetes Res; 2024; 2024():9985836. PubMed ID: 38766320
[No Abstract] [Full Text] [Related]
2. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
3. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
4. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS; Bhatt DL; Hameed I; Anker SD; Cheng AYY; Hernandez AF; Jones WS; Khan MS; Petrie MC; Udell JA; Friede T; Butler J
Lancet Diabetes Endocrinol; 2024 Jul; 12(7):447-461. PubMed ID: 38768620
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin on Ventricular Remodeling and Prognosis in Patients with Coronary Atherosclerotic Heart Disease Undergoing Percutaneous Coronary Intervention.
Ye L; Wang K; Sheng H; Shi X; Yan L
Altern Ther Health Med; 2024 Apr; 30(4):204-208. PubMed ID: 37944964
[TBL] [Abstract][Full Text] [Related]
7. [Effects of Dapagliflozin on contrast-induced acute kidney injury in patients with type 2 diabetes mellitus underwent percutaneous coronary intervention].
Yang SC; Ma YF; Zhang P; Cong HL; Fu NK
Zhonghua Yi Xue Za Zhi; 2024 Jun; 104(22):2059-2065. PubMed ID: 38858216
[No Abstract] [Full Text] [Related]
8. Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study.
Moady G; Yakubovich I; Atar S
J Cardiovasc Pharmacol Ther; 2024; 29():10742484241252474. PubMed ID: 38711298
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data.
Wang W; Chen LY; Walker RF; Chow LS; Norby FL; Alonso A; Pankow JS; Lutsey PL
Mayo Clin Proc; 2023 Jul; 98(7):985-996. PubMed ID: 37419588
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis.
Felix N; Gauza MM; Teixeira L; Guisso MES; Nogueira A; Dagostin CS; Godoi A; Ribeiro SAG; Duque JC; Moura-Neto JA; Cardoso R
Korean Circ J; 2024 Apr; ():. PubMed ID: 38859642
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 inhibitors: a swinging pendulum in the treatment of acute myocardial infarction.
Aziri B; Begic E; Stanetic B; Mladenovic Z; Kovacevic-Preradovic T
Minerva Cardiol Angiol; 2024 Jun; 72(3):237-250. PubMed ID: 37161919
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Acute Coronary Syndrome.
Song J; Liu Y; Xu Y; Hao P
ACS Pharmacol Transl Sci; 2024 Jun; 7(6):1847-1855. PubMed ID: 38898953
[TBL] [Abstract][Full Text] [Related]
13. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
Sharma A; Zheng Y; Ezekowitz JA; Westerhout CM; Udell JA; Goodman SG; Armstrong PW; Buse JB; Green JB; Josse RG; Kaufman KD; McGuire DK; Ambrosio G; Chuang LM; Lopes RD; Peterson ED; Holman RR
Diabetes Care; 2022 Jan; 45(1):204-212. PubMed ID: 34716214
[TBL] [Abstract][Full Text] [Related]
14. The Role of Sodium-Glucose Co-transporter 2 Inhibitors in Patients With Hypomagnesemia: A Systematic Review.
Singh MP; Agrawal N; Agrawal A; Kushwah SS; Krishna E; Singh JM
Cureus; 2024 May; 16(5):e60919. PubMed ID: 38910615
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.
Tamez-Perez HE; Delgadillo-Esteban E; Soni-Duque D; Hernández-Coria MI; Tamez-Peña AL
J Diabetes Metab Disord; 2017; 16():27. PubMed ID: 28680862
[TBL] [Abstract][Full Text] [Related]
16. As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
Pinney SP; Costanzo MR
J Am Coll Cardiol; 2024 Jun; 83(24):2423-2425. PubMed ID: 38866446
[No Abstract] [Full Text] [Related]
17. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors:
Dabour MS; George MY; Daniel MR; Blaes AH; Zordoky BN
JACC CardioOncol; 2024 Apr; 6(2):159-182. PubMed ID: 38774006
[TBL] [Abstract][Full Text] [Related]
18. Cardio-renoprotective effects of SGLT2 inhibitors-the role of anaemia correction.
Locatelli F; Del Vecchio L
Nephrol Dial Transplant; 2024 May; 39(6):904-906. PubMed ID: 38263523
[No Abstract] [Full Text] [Related]
19. Risk of perioperative discontinuation of SGLT2 inhibitors.
Oosterom-Eijmael MJP; Hermanides J; van Raalte DH; Hulst AH
Br J Anaesth; 2024 Jun; ():. PubMed ID: 38834489
[TBL] [Abstract][Full Text] [Related]
20. Are Sodium-Glucose Cotransporter-2 Inhibitors Fantastic for Coronary Plaque Stabilization?
Minami Y; Iwaya T
Am J Cardiol; 2024 Jul; 222():95. PubMed ID: 38718913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
